¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

2019 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ : 2019-12-06

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 
2019 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ : 2019-12-06
±³À°ÀÏÀÚ : 2019-12-06
±³À°Àå¼Ò : ±×·£µå ¿öÄ¿Èú È£ÅÚ ºñ½ºÅ¸È¦B2F  
±³À°ÁÖÁ¦ : 2019 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ
ÁÖÃÖ±â°ü : ´ëÇѾȰúÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Çѱ¹¸Á¸·ÇÐȸ  
´ã´çÀÚ : ¹ÚÀ±Á¤
¿¬¶ôó : 02-471-6520  
À̸ÞÀÏ : retina@retina.or.kr      
±³À°Á¾·ù : ¾È°ú      
Âü¼®¿¹»óÀοø : 250¸í
Èñ¸ÁÆòÁ¡ : 4Á¡  
Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 7 ½Ã°£ 53ºÐ  
¼¼ºÎ¼ö°­·á : 100,000¿ø      
ºñ°í »çÀüµî·Ï: Àü°ø/ÀüÀÓÀÇ 6¸¸¿ø Àü¹®ÀÇ 8¸¸¿ø ÇöÀåµî·Ï: Àü°ø/ÀüÀÓÀÇ 8¸¸¿ø Àü¹®ÀÇ 10¸¸¿ø      

±¸ºÐ ¿ùÀÏ °­ÀǽǠ½Ã°£ ±³À°Á¦¸ñ  °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 12-06  09:00~09:08 Injectable Drug-Loaded Core/Shell Rod for Temporally Controlled Delivery of Bevacizumab and Dexamethasone: A Prolonged and Synergetic Therapy for Retinal Vascular Diseases  ¿øÀ翬(°¡Å縯´ë) 
±³À°½Ã°£ 12-06  09:08~09:16 Quantitative evaluation of choriocapillaris using optical coherence tomography and optical coherence tomography angiography in patients with central serous chorioretinopathy after half-dose photodynam  ¾çÇö½Â(½Å¼¼°è¾È°ú) 
±³À°½Ã°£ 12-06  09:16~09:24 Çѱ¹Àο¡¼­ Ȳ¹ÝºÎ ¸ð¼¼Ç÷°üÈ®ÀåÁõ 2ÇüÀÇ ÀÓ»ó¾ç»ó ºÐ¼®: ´Ù±â°ü °øµ¿¿¬±¸  À̱âȲ(¾ÆÁÖ´ë) 
±³À°½Ã°£ 12-06  09:24~09:32 Inhibition of mTOR via an AAV-delivered shRNA tested in a rat OIR model as a potential anti-angiogenic gene therapy  ÀÌÁÖ¿ë(¿ï»ê´ë) 
±³À°½Ã°£ 12-06  09:32~09:40 Descriptive Epidemiology for Common Retinal Diseases from the National Claims Database  ¹Ú»óÁØ(¼­¿ï´ë) 
±³À°½Ã°£ 12-06  10:00~10:15 Let's dig deep into eye: from classification to image generation using deep learning  ¼Û¼öÁ¤(¼º±Õ°ü´ë) 
±³À°½Ã°£ 12-06  10:15~10:45 AI in Ophthalmology  Daniel Ting Shu Wei(Singapore national eye center) 
±³À°½Ã°£ 12-06  10:45~11:00 Artificial intelligence  ±ÇÁظí(¼¼Á¾º´¿ø) 
±³À°½Ã°£ 12-06  11:20~11:35 What can we predict with OCTA for inrtravitreal injection  ±è¼º¿ì(°í·Á´ë) 
±³À°½Ã°£ 12-06  11:35~11:50 Myopic Tractional Maculopathy - Surgical consideration  °íÇüÁØ(¿¬¼¼´ë) 
±³À°½Ã°£ 12-06  11:50~12:20 Ultra wide-field OCT of vitreoretinal observation  Kyoko Ohno-matsui(Tokyo Univ.) 
±³À°½Ã°£ 12-06  12:30~13:00 Lucentis Optimal treatment option for DME patient  À̱âȲ(¾ÆÁÖ´ë) 
±³À°½Ã°£ 12-06  13:00~13:30 Why are we insensitive to safety issue of anti-VEGF?  ±èÀ¯Ã¶(°è¸í´ë) 
±³À°½Ã°£ 12-06  14:00~14:15 ROP vitrectomy  Shunji KUSAKA(Kimdai Univ.) 
±³À°½Ã°£ 12-06  14:15~14:30 Various phenotypes and genetics of FEVR  ±è»óÁø(¼º±Õ°ü´ë) 
±³À°½Ã°£ 12-06  14:30~14:45 Surgical Management of FEVR  Shunji KUSAKA(Kindai Univ.) 
±³À°½Ã°£ 12-06  14:45~15:00 Pediatric retinal detachment and stickler syndrome  ¿ì¼¼ÁØ(¼­¿ï´ë) 
±³À°½Ã°£ 12-06  15:20~15:35 Next Generation Analysis of Patient-derived Membranes in Proliferative Vitreoretinopathy  Leo Kim(Harvard Univ.) 
±³À°½Ã°£ 12-06  15:35~16:05 Dual Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in nAMD: Results of Phase 2 Trials  Nicholas Fung(Hong Kong Univ.) 
±³À°½Ã°£ 12-06  16:05~16:20 Examining Brolucizumab Data  À¯½Â¿µ(°æÈñ´ë) 
±³À°½Ã°£ 12-06  16:20~16:35 Anti-VEGF biosimilar for neovascular AMD  À¯Çü°ï(¼­¿ï´ë) 
±³À°½Ã°£ 12-06  16:35~16:45 Àΰø¸Á¸·°³¹ßÀÇ ¾î·Á¿ò°ú ¹Ì·¡  ¼­Á¾¸ð(¼­¿ï´ë) 
±³À°½Ã°£ 12-06  17:00~17:08 Association of age-related macular degeneration with Alzheimer¡¯s disease and Parkinson¡¯s disease  Áöµ¿Çö(°¡Å縯´ë) 
±³À°½Ã°£ 12-06  17:08~17:16 Differential proteins in the aqueous humor from patients with drusen and reticular pseudodrusen  Á¤Çý¿ø(°Ç±¹´ë) 
±³À°½Ã°£ 12-06  17:16~17:24 Changes in OCT angiography and disease activity in type 3 neovascularization after anti-vascular endothelial growth factor treatment  Á¶ÇÑÁÖ(±è¾È°úº´¿ø) 
±³À°½Ã°£ 12-06  17:24~17:32 Choroid and choriocapillaris in non-exudative age related macular degeneration  À±Ã¶¹Î(°í·Á´ë) 
±³À°½Ã°£ 12-06  17:32~17:40 Increase in the Population of Patients with Neovascular Age-Related Macular Degeneration Who Underwent Long-Term Active Treatment  ±èÀçÈÖ(±è¾È°ú) 
±³À°½Ã°£ 12-06  17:40~17:48 Depression and anxiety of patients with neovascular age-related macular degeneration according to related factors.  ±èÁø¿µ(Á¦ÁÖ´ë) 
±³À°½Ã°£ 12-06  18:00~18:30 The Role of Steroids in the Management of Diabetic Macular Edema  ±èÁ¤¿­(Ãæ³²´ë) 
±³À°½Ã°£ 12-06  18:30~19:00 Personalized management of DME with early Ozurdex treatment  ÀÌÁöÀº(ºÎ»ê´ë) 
ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" 2019 Çѱ¹¸Á¸·ÇÐȸ ÃÑȸÇмú´ëȸ : 2019-12-06""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¼­¿ï¾Æ»êº´¿ø Á¦ 20Â÷ ¿Ü°úº´¸® ¿¬¼ö±³À° : 2019-12-06
´ÙÀ½±Û º£½ºÆ¼¾Èº´¿ø 2019 ´ëÇÑÈ­»óÇÐȸ ½ÉÆ÷Áö¿ò : 2019-12-06
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20925 ÀüºÏ Á¦ 53Â÷ ´ëÇѳëÀκ´ÇÐȸ È£³²Áöȸ ÇмúÁý´äȸ : 2024-07-27 0 12 2024-05-28
20924 ¼­¿ï 2024 Á¦27ȸ ´ëÇѾȸ鼺ÇüÀç°ÇÇÐȸ Ãá°è Çмú´ëȸ : 2024-07-21 0 17 2024-05-28
20923 °æ±â 2024³â ÀÏ»ê¹éº´¿ø Á¤Çü¿Ü°ú ½ÉÆ÷Áö¾ö : 2024-07-21 0 9 2024-05-28
20922 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(2ÀÏÂ÷) : 2024-07-20 0 6 2024-05-28
20921 ¼­¿ï Á¦33Â÷ ´ç´¢º´ ¿¬±¸ ÇÏ°è¿öÅ©¼¥ : 2024-07-20 0 8 2024-05-28
20920 ¼­¿ï ´ëÇÑÁ¾¾ç³»°úÇÐȸ Recent updates in GU Cancers 2024 : 2024-07-19 0 11 2024-05-28
20919 ¼­¿ï 2024³â ü°èÀû ¹®Çå°íÂû(¸ÞŸºÐ¼®) ³í¹®Ãâ°£ ¿öÅ©¼¥ 2Â÷(1ÀÏÂ÷) : 2024-07-19 0 4 2024-05-28
20918 ¼­¿ï [¿Â¶óÀÎ] Áø´Ü¿ë ¹æ»ç¼± ¾ÈÀü°ü¸®Ã¥ÀÓÀÚ ¼±ÀÓ±³À° : 2024-07-14 0 4 2024-05-28
20917 °æºÏ 2024³â ´ëÇÑ°ñ´Ù°øÁõÇÐȸ ¿µ³² ¿¬¼ö°­Á : 2024-07-14 0 3 2024-05-28
20916 °æ±â ÀÎÁ¦´ëÇб³ ÀÏ»ê¹éº´¿ø ¼ÒÈ­±â³»°ú °³¿øÀÇ ¿¬¼ö°­Á : 2024-07-13 0 6 2024-05-28
20915 °æ±â 2024³â ÀÇÁ¤ºÎÀ»Áö´ëÇб³º´¿ø Á¦1ȸ ½Å°æ°ú °³¿øÀÇ ¿¬¼ö±³À° : 2024-07-13 0 6 2024-05-28
20914 ºÎ»ê Á¦6ȸ ºÎ»ê¼º¸ðº´¿ø ¼Ò¾Æû¼Ò³â°ú ½ÉÆ÷Áö¾ö : 2024-07-13 0 4 2024-05-28
20913 ¼­¿ï 2024 ´ëÇѽŰ泻ºÐºñ¿¬±¸È¸ ¿¬¼ö°­Á : 2024-07-13 0 5 2024-05-28
20912 ¼­¿ï ÀºÆò±¸ÀÇ»çȸ Á¦3Â÷¿¬¼ö±³À° : 2024-07-11 0 4 2024-05-28
20911 ¼­¿ï (¿Â¶óÀÎ) 2024³â ¼Ò¾Æ½ÅÀå Post-graduate education course : 2024-07-08 0 7 2024-05-28
1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷